The PD-L1 expression levels of tumor-infiltrating CD45+ cells were increased in tumors from mice treated with TTFields in combination with anti-PD-1 as compared to the control group, suggesting elevated inflammatory response in these tumors. Here, PTPRC is linked to neoplasm.